Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (40)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cardoso, F.
Right arrow Articles by Piccart, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cardoso, F.
Right arrow Articles by Piccart, M. J.
Related Collections
Right arrow 2002 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:197-207, 2002
© 2002 European Society for Medical Oncology

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

F. Cardoso, A. Di Leo,+, C. Lohrisch, C. Bernard, F. Ferreira and M. J. Piccart

Department of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium

Received 22 August 2001; revised 22 October 2001; accepted 15 November 2001.

‘It matters not how long we live, but how.’

Festus, Philip James Bailey

Despite almost 30 years of clinical cancer research, the true impact of second and subsequent lines of chemotherapy on the outcome of metastatic breast cancer patients, especially on the duration of survival, is still unknown. In the virtually incurable metastatic setting, issues like quality of life and patients’ preferences gain particular relevance. At the turn of the century, in-depth rethinking of the design of clinical trials run in this challenging disease setting appears to be warranted.

Key words: breast cancer, metastatic, quality of life, second line


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. A. Perez, D. W. Hillman, T. Dentchev, N. A. Le-Lindqwister, L. H. Geeraerts, T. R. Fitch, H. Liu, D. L. Graham, S. P. Kahanic, H. M. Gross, et al.
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
Ann. Onc., February 1, 2010; 21(2): 269 - 274.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
K. R. Sepucha, E. M. Ozanne, A. H. Partridge, and B. Moy
Is There a Role for Decision Aids in Advanced Breast Cancer?
Med Decis Making, July 1, 2009; 29(4): 475 - 482.
[Abstract] [PDF]

Home page
 JCOHome page
S. Dawood, K. Broglio, A. M. Gonzalez-Angulo, A. U. Buzdar, G. N. Hortobagyi, and S. H. Giordano
Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer
J. Clin. Oncol., October 20, 2008; 26(30): 4891 - 4898.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Oncologist, March 1, 2007; 12(3): 253 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W Ichikawa and Y Sasaki
Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients
Ann. Onc., November 1, 2006; 17(11): 1665 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Grunfeld, E. J. Maher, S. Browne, P. Ward, T. Young, B. Vivat, G. Walker, C. Wilson, H. W. Potts, A. M. Westcombe, et al.
Advanced Breast Cancer Patients' Perceptions of Decision Making for Palliative Chemotherapy
J. Clin. Oncol., March 1, 2006; 24(7): 1090 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Bernard-Marty, F. Cardoso, and M. J. Piccart
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Oncologist, November 1, 2004; 9(6): 617 - 632.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. T. Chung and R. W. Carlson
Goals and Objectives in the Management of Metastatic Breast Cancer
Oncologist, December 1, 2003; 8(6): 514 - 520.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.